Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
The development of a paper-based, point-of-care diagnostic test may enable clinicians to rapidly detect bacterial infections and their antibiotic susceptibility with a simple colorimetric readout.
This opinion piece looks at the impact a precision (or personalized) medicine approach could have in sepsis, including early and accurate microbiologic diagnosis, determining the host immune response signature and assessing individual response to treatment.
Precision medicine is an approach to patient care that aims for the right intervention, in the right patient, at the right time – but what impact could this have on the treatment of infectious diseases? We asked Mathias Pletz about this approach to treatment, the research he’s directing at his institute and what the challenges are in this field.
The WHO have updated their recommendations on HIV testing in order to try and expand treatment coverage and reach the people living with HIV who are not yet diagnosed.
For the first time a team of researchers have discovered clear signs of enterovirus in acute flaccid myelitis patients, strongly suggesting that the disease is viral.
A novel phage-based blood assay has demonstrated its potential for identifying people at high-risk of developing tuberculosis, in addition to diagnosing established cases.
In this interview we speak to David Padley from the National Institute for Biological Standards and Control about his recent poster ‘Point-of-Care testing for HIV: specialist quality control materials are a necessity’, presented at ECCMID 2019.
New research has identified four novel sepsis phenotypes, suggesting these could be relevant for understanding the heterogeneity of treatment effects and help to explain recent clinical trial failures.
The ECDC has reported that the burden of healthcare-associated infections is substantial and variability in microbiological testing suggests these infections could be managed better, according to research presented at ECCMID.
